First Clear Win for BTK Inhibitors in Relapsing MS

After previous disappointments with BTK inhibitors, a novel drug in this class is the first to show superiority to an active comparator for relapsing MS outcomes. Medscape Medical News
Take Your Experience to the Next Level
NewDownload our mobile app for a faster and better experience.
Comments
0U
Join the discussion
Sign in to leave a comment